Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver after Local Administration in Mice

Delivery of messenger RNA (mRNA) by using lipid nanoparticles (LNPs) is expected to be applied to various diseases after the successful clinical use of the mRNA COVID-19 vaccines. This study aimed to evaluate the effect of the Cholesterol molar percentage of mRNA-LNPs on protein expression in hepatocellular carcinoma-derived cells and in the liver after intramuscular or subcutaneous administration of mRNA-LNPs in mice. For mRNA-LNPs with Cholesterol molar percentages reduced to 10 mol% and 20 mol%, we formulated neutral charge particles of approximately 100 nm diameter and polydispersity index (PDI) < 0.25. After the intramuscular or subcutaneous administration of mRNA-LNPs with different Cholesterol molar percentages in mice, protein expression in the liver decreased as the Cholesterol molar percentage in mRNA-LNPs decreased from 40 mol% to 20 mol% and 10 mol%, suggesting that reducing the Cholesterol molar percentage in mRNA-LNPs decreases protein expression in the liver. Furthermore, in HepG2 cells, protein expression decreased as Cholesterol in mRNA-LNPs was reduced by 40 mol%, 20 mol%, and 10 mol%. These results suggest that the downregulated expression of mRNA-LNPs with low Cholesterol content in the liver involves degradation in systemic circulating blood and decreased protein expression after hepatocyte distribution.

Drug delivery systems; Lipid nanoparticles (LNPs); Messenger ribonucleic acid (mRNA), Intramuscular administration.